ArticleBlood advances2023
The utility of biomarkers in acute GVHD prognostication.
Abstract read
In one paragraph
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Trial
- MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.medRxiv : the preprint server for health sciences · 2026Article
- System-level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated With High One-year Survival and Reduced Cost.Transplantation and cellular therapy · 2026Article
- Biomarker-driven strategies and challenges in acute graft-versus-host disease clinical trials.International journal of hematology · 2026Review
- Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.Blood immunology & cellular therapy · 2026Article
- The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.Blood advances · 2025Article
- DecodingAcute GVHD: The role of serum biomarkers and imaging in diagnosis and management.Blood reviews · 2025Review
- Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC.Blood advances · 2025Article
- Prediction and Prognostication of Acute Graft-Versus-Host Disease by MAGIC Biomarkers.American journal of hematology · 2025Review
- Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.Transplantation and cellular therapy · 2025Article
- Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.Transplantation and cellular therapy · 2024Article
- Article
- The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.Blood advances · 2024Article
- Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD.Blood advances · 2024Article
- A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.Transplantation and cellular therapy · 2024Article
- Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis.Blood advances · 2024Article
- Steroid tapering after GVHD Rx: not too fast, not too slow.Blood advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Nikolaos SpyrouThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0001-5274-1749
Yu AkahoshiThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0001-6825-9340
Francis AyukDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ernst HollerDepartment of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany.
Hannah ChoeDivision of Hematology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
Aaron EtraThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
William J HoganDivision of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-5841-4105
Wolf RöslerDepartment of Internal Medicine 5, Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany.
Elizabeth HexnerBlood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-1125-4060
Zachariah DeFilippHematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA.ORCID 0000-0002-7994-8974
Ran ReshefBlood and Marrow Transplantation Program, Columbia University Medical Center, New York, NY.
Chantiya ChanswangphuwanaDepartment of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Muna QayedAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.ORCID 0000-0001-7689-343X
Sabrina KrausDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Matthias EderDepartment of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Nora Rebeka JavorniczkyDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, Albert Ludwigs University, Freiburg, Germany.
Stephan A GruppDivision of Oncology, Children's Hospital of Philadelphia and Perelman School of Medicine, Philadelphia, PA.
Carrie L KitkoPediatric Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, TN.
Pietro MerliDepartment of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Rome, Italy.ORCID 0000-0001-6426-4046
Paibel Aguayo-HiraldoDivision of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital of Los Angeles, Los Angeles, CA.ORCID 0000-0002-0196-806X
Matthias WölflPediatric Blood and Marrow Transplantation Program, Children's Hospital, University of Würzburg, Würzburg, Germany.
Janna BaezThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Rahnuma BeheshtiThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Gilbert EngThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Sigrun GleichDepartment of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany.
Nikolaos KatsivelosThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0009-0004-7955-1119
Alina KhanThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Steven KowalykThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
George MoralesThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Rachel YoungThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Ryotaro NakamuraHematology/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0002-9082-0680
Yi-Bin ChenHematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA.ORCID 0000-0002-9554-1058
John E LevineThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-5611-7828
James L M FerraraThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Funding
TUMOR VACCINES AND BONE MARROW TRANSPLANTATIONP01CA039542 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JAMES L. M. FERRARA · 1985 to 2026
$47.9MTHE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Deanna L Benson · 2015 to 2026
$35.4MNCI NIH HHS P01 CA039542NCI NIH HHS P30 CA196521
Abstract
PubMed holds no abstract for this paper.
Indexed as
Graft vs Host DiseaseBiomarkersHumansTransplantation, HomologousBiomarkers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.